Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02242552|
Recruitment Status : Unknown
Verified August 2014 by Dr Monia Marzouki, St. Justine's Hospital.
Recruitment status was: Recruiting
First Posted : September 17, 2014
Last Update Posted : September 17, 2014
A new research paradigm that involves sequencing tumor DNA/RNA to identify driver mutations, select among the Health Canada approved drugs (for adult cancers) known to block certain oncogenic pathways, and recommend these drugs to the treating physician, without taking into account the tumor histology.
In this paradigm, the treatment is targeted to the actionable mutation(s) i.e. those driving oncogenesis. It is also personalized to the molecular signature of the patient's tumor, irrespective of its histopathological subtype. The experience of the investigators team in genomics, including next generation sequencing and bioinformatic analysis combined with the clinical expertise, bring at last this approach within our technical capacities. In parallel, the number of Health Canada-approved drugs (which have been tested in a pediatric setting) designed to interfere with oncogenesis pathways is increasing exponentially.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood(TRICEPS Study)|
|Study Start Date :||June 2014|
|Estimated Primary Completion Date :||June 2016|
|Estimated Study Completion Date :||June 2017|
- Feasibility of performing genomic data-based targeted therapy clinical trials in childhood cancers with poor prognosis, including relapsed or refractory cancers. [ Time Frame: 24 months ]The study team will evaluate the timeline between decision of biopsy, the actual biopsy, availability of results of the whole-genome analysis, interpretation of results and divulgation of results to patient and family.
- Number of children with cancer who are suitable candidates for targeted therapy at our institution each year. [ Time Frame: 24 months ]
- Number and type of driver mutation(s) found in our population of recurrent or refractory cancers. [ Time Frame: 24 months ]
- Number of cancer patients who harbour actionable driver mutation(s) that can be targeted with a Health Canada approved targeted drug. [ Time Frame: 24 months ]
- Feasibility of performing whole genome sequencing and data analysis, identifying a drug based on the genomic data and offering this information to the medical team, the patient and the family within 10-week time frame from diagnosis [ Time Frame: 24 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02242552
|Contact: Monia Marzouki, MD||514-345-4931 ext firstname.lastname@example.org|
|Contact: Hemrique Bittencourt, MD||514-345-4931 ext email@example.com|
|Montréal, Quebec, Canada, H3T1C5|
|Contact: Dominique Lafrenière, BScN, DESS 514-345-4969 firstname.lastname@example.org|
|Contact: Mary-Ellen French, RN 514-345-4969 email@example.com|
|Principal Investigator:||Monia Marzouki, MD||St. Justine's Hospital|